Recent news coverage includes general market and commodity updates without direct company-specific developments. The company’s strategic updates and financial restatements are primarily disclosed through SEC filings.

• NovaBay Pharmaceuticals announced a corporate name change to Stablecoin Development Corporation and a ticker change to SDEV effective April 2026, reflecting a strategic shift to blockchain and digital asset activities [S1].
• The company holds approximately 2.15 billion SKY tokens as of March 31, 2026, and engages in staking activities related to these digital assets [S1].
• The 2026 Equity Incentive Plan was approved by stockholders in March 2026, granting restricted stock units and performance-based awards to executives to align compensation with long-term value creation [S1].
• The company reported a restated net loss of $630.78 million for the fiscal year ended December 31, 2025, primarily due to non-cash warrant accounting adjustments [S1].
• Liquidity remains strong with cash and equivalents of $7.958 million and a current ratio of 7.6 as of December 31, 2025 [S1].

The company’s strategic shift to digital asset holdings and staking activities, supported by a large token balance and executive incentives aligned with long-term value creation, could position it to capitalize on emerging blockchain opportunities. Strong liquidity provides financial flexibility during this transition. The restatement of financials clarifies prior accounting issues, potentially improving transparency and investor confidence.

The company faces risks from its significant net losses driven by non-cash warrant accounting adjustments, which may impact financial perception. The transition from pharmaceuticals to blockchain-related activities introduces execution risk and uncertainty about future revenue streams. The lack of recent revenue data and the nascent nature of its new business model may challenge visibility and valuation. Market volatility in digital assets and regulatory uncertainties add to the risk profile.

The company’s moat is currently limited due to its transition from pharmaceuticals to digital asset activities, a sector characterized by rapid innovation and competition. Its significant holdings of SKY tokens and engagement in staking may provide some strategic positioning in blockchain ecosystems. However, the lack of disclosed pharmaceutical product revenues and the ongoing corporate transformation suggest the moat is under development and subject to execution risks.

• Accounting and Financial Reporting Risk: The company restated its 2025 financial statements due to errors in accounting for pre-funded warrants, resulting in a large non-cash net loss. Such issues may affect investor confidence and financial transparency.
• Business Model Transition Risk: The shift from pharmaceuticals to blockchain and digital asset activities involves execution risk, including the ability to generate sustainable revenues and adapt to a new industry landscape.
• Market and Regulatory Risk: Engagement in digital assets and staking exposes the company to market volatility and evolving regulatory frameworks that could impact operations and asset valuations.

• NovaBay Pharmaceuticals, Inc. is a Delaware corporation with common stock trading under the ticker NBY on the NYSE American exchange as of the report date.
• The company filed a 10-K/A annual report on April 29, 2026, covering the fiscal year ended December 31, 2025, which includes restated financial statements due to accounting errors related to pre-funded warrants.
• NovaBay Pharmaceuticals underwent a corporate name change to Stablecoin Development Corporation effective April 2, 2026, with a ticker symbol change to SDEV expected on April 6, 2026.
• The company holds significant digital asset holdings, including approximately 2.15 billion SKY tokens as of March 31, 2026, and engages in on-chain activities such as staking.
• The company adopted a 2026 Equity Incentive Plan approved by stockholders on March 12, 2026, granting restricted stock units and performance-based awards to executives to align compensation with long-term stockholder value.
• The CEO, Michael Kazley, and CFO, Tommy Law, have employment agreements effective March 31, 2026, with specified base salaries, bonus eligibility, and severance benefits.
• Financial snapshot as of December 31, 2025, shows cash and cash equivalents of $7.958 million, current assets of $8.675 million, and current liabilities of $1.142 million, resulting in a current ratio of 7.6 and a cash ratio of 6.97, indicating strong liquidity.
• The company reported a net loss of $630.78 million for the fiscal year ended December 31, 2025, primarily due to non-cash accounting adjustments related to warrant liabilities.
• Basic earnings per share for 2025 were -$108.39, with diluted EPS of -$0.22 as of Q3 2025.
• The company’s revenue figure from Q1 2015 was $46,000, with no recent revenue data disclosed in the latest filings.
• The company’s business model appears to be transitioning from pharmaceuticals to blockchain and digital asset-related activities, as indicated by the name change and disclosed staking activities.